Botulinum Toxin in Neuromodulation: Current Advances in Migraine Treatment
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 32
Special Issue Editor
Interests: clinical neurology; adult neurology; headache; botulinum toxins
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic migraine, defined as headache occurring on 15 or more days per month for more than three months, with features of migraine on at least 8 days per month, represents a highly disabling condition associated with personal, social, and economic burden.
Following the pivotal results of the PREEMPT studies (Phase III REsearch Evaluating Migraine Prophylaxis Therapy), Botulinum toxin type A (BoNT-A) has been approved for chronic migraine prevention and is now recommended by major international and national guidelines, including the recently updated SISC-IHS joint guidelines, as well as those of the European Headache Federation (EHF) and the American Headache Society (AHS). These guidelines recognize botulinum toxin as an effective and safe first-line prophylactic treatment in appropriately selected patients with chronic migraine, particularly when oral preventives are ineffective or poorly tolerated.
BoNT-A efficacy in migraine is believed to be linked to modulation of the nociceptive pathways, achieved through the inhibition of neuropeptide release (such as CGRP, substance P, and glutamate) at the peripheral and possibly central level. By interfering with neurogenic inflammation and peripheral sensitization, BoNT-A contributes to reducing the frequency and intensity of migraine attacks, opening new avenues in the field of neuromodulation.
This Special Issue aims to explore the current advances, clinical applications, and mechanistic insights regarding botulinum toxin in the treatment of migraine. We welcome original research, reviews, clinical studies addressing the multifaceted role of BoNT-A in migraine therapy.
Topics of interest include (but are not limited to):
- Mechanisms of action in migraine pathophysiology
- Clinical efficacy in chronic and episodic migraine
- Emerging injection techniques and neuromodulation protocols
- Patient stratification and personalized treatment approaches
- Combination therapies (e.g., with CGRP antagonists or neuromodulation devices)
- Safety profile, tolerability, and long-term outcomes
- Experimental models and translational research including studies that bridge basic science and clinical application (e.g., molecular mechanisms, experimental models, or early-phase clinical investigations aimed at informing therapeutic use)
This collection seeks to foster interdisciplinary discussion and promote innovation in migraine management through neuromodulatory strategies involving botulinum toxin.
Dr. Maria Pia Prudenzano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- botulinum toxin (BoNT)
- migraine treatment
- neuromodulation
- chronic migraine
- prophylactic therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
